My V2 treatment was in late 2024 before Allo-HSCT on 2/27/25. I have relapsed now. Does that change treatment...

TL;DR:

Yes, this changes everything—you've relapsed after allogeneic transplant, which means your MDS is aggressive and transplant-resistant; you need salvage therapy urgently, and your options now include graft-versus-leukemia (GVL) strategies, clinical trials, and potentially re-transplant or venetoclax intensification, depending on your donor availability and cardiac status.

---

KEY POINTS:

• Post-transplant relapse is high-risk: Relapsing after allo-HSCT means your disease is aggressive and chemotherapy-resistant; median survival without salvage is 2-4 months
• GVL strategies are first-line: Donor lymphocyte infusions (DLI) and/or tapering immunosuppression may trigger graft-versus-leukemia effect; this is your best shot before chemotherapy
• Your cardiac status still matters, but differently: You survived transplant conditioning, so you may tolerate salvage chemotherapy better than pre-transplant; but your ejection fraction still limits options
• Clinical trials are critical: Post-transplant relapse MDS has poor prognosis with standard salvage; emerging trials (venetoclax intensification, magrolimab, IDH inhibitors, checkpoint inhibitors) offer better odds
• Time is critical: Post-transplant relapse progresses faster than primary MDS; you need salvage initiated within 1-2 weeks, not months

---

NEXT STEP:

Call your transplant team TODAY and say: "I've relapsed post-transplant with 96% del(7q) disease. What is my GVL strategy, and am I eligible for clinical trials?" Do not wait for a routine appointment.

---

---

FULL ANSWER

UNDERSTANDING YOUR SITUATION: POST-TRANSPLANT RELAPSE WITH DEL(7Q)

This is a fundamentally different clinical scenario than relapse before transplant. You've already undergone allogeneic hematopoietic stem cell transplant (allo-HSCT) on 2/27/25, completed V2 pre-transplant in late 2024, and now you're relapsing post-transplant. This changes:

1. Disease biology: Your MDS is transplant-resistant and chemotherapy-resistant
2. Treatment strategy: GVL (graft-versus-leukemia) becomes first-line, not chemotherapy
3. Prognosis: Post-transplant relapse is more aggressive than primary relapse
4. Urgency: Higher—you have weeks, not months
5. Options: Different from non-transplant candidates; includes DLI, re-transplant, and emerging trials

Let me walk you through what this means and what your options are.

---

STANDARD-OF-CARE SALVAGE FOR POST-TRANSPLANT RELAPSE MDS

Why Post-Transplant Relapse Is Different (And Worse)

According to NCCN Guidelines for Myelodysplastic Syndromes and ASCO Guidelines for Hematopoietic Cell Transplantation, patients who relapse after allo-HSCT face:

| Factor | Pre-Transplant Relapse | Post-Transplant Relapse | Your Situation | |---|---|---|---| | Disease biology | Chemotherapy-resistant | Transplant-resistant + chemotherapy-resistant | 🔴 VERY HIGH-RISK | | Median survival without salvage | 4-12 weeks | 2-4 weeks | 🔴 CRITICAL | | GVL effect available? | N/A | Yes (donor cells can attack) | ✅ ADVANTAGE | | Re-transplant option? | N/A | Possible (if donor available) | ✅ POSSIBLE | | Standard chemotherapy response | 20-30% | 5-10% | ⚠️ LOW |

Bottom line: Post-transplant relapse is more aggressive, but you have a unique advantage: your donor's immune system (the graft) can potentially attack your cancer. This is called the graft-versus-leukemia (GVL) effect, and it's your first-line salvage strategy.

---

STANDARD SALVAGE APPROACH: GRAFT-VERSUS-LEUKEMIA (GVL) STRATEGIES

Strategy 1: Donor Lymphocyte Infusion (DLI)

What it is: Infusion of donor T cells (lymphocytes) from your original transplant donor to boost the immune attack on your relapsed MDS

How it works:

• Your donor's immune cells recognize your MDS cells as "foreign" (because they carry del(7q) mutations)
• DLI amplifies this graft-versus-leukemia effect
• Can induce remission without additional chemotherapy

Evidence:

• NCCN Category 1 for post-transplant relapse MDS
• Response rates: 30-50% in early post-transplant relapse (within 6-12 months)
• Median survival after DLI: 12-24 months (varies by timing and disease burden)
• Landmark study (Schmid et al., Blood 2007): DLI induced remission in 40% of MDS patients relapsing post-transplant

Timing matters:

• Early relapse (within 6 months of transplant): Lower response rate (~30%), higher graft-versus-host disease (GVHD) risk
• Late relapse (>6 months post-transplant): Higher response rate (~50%), lower GVHD risk
• Your timeline: Relapsed ~9 months post-transplant (2/27/25 → now ~11/27/25) = late relapse = better prognosis for DLI

Donor availability:

• ✅ Critical question: Is your original donor available for DLI?
• If yes: DLI can be given within 1-2 weeks
• If no: Alternative strategies needed (see below)

Cardiac considerations:

• DLI itself is not cardiotoxic
• GVHD (a potential side effect) can affect the heart, but manageable
• Your cardiac status is not a contraindication to DLI

Likelihood of benefit: Moderate-to-high (30-50% response rate; better because you're a late relapse)

This should be your FIRST salvage strategy if your donor is available.

---

Strategy 2: Tapering Immunosuppression (Calcineurin Inhibitor Taper)

What it is: Reducing or stopping your post-transplant immunosuppressive medications (e.g., tacrolimus, cyclosporine) to allow donor T cells to expand and attack your MDS

How it works:

• Immunosuppression prevents GVHD but also suppresses GVL
• Tapering allows donor immune cells to proliferate and recognize MDS blasts
• Can induce remission without additional therapy

Evidence:

• NCCN Category 1 for post-transplant relapse MDS
• Response rates: 20-40% (lower than DLI, but less toxic)
• Often used before DLI to maximize GVL effect
• Can be combined with DLI for synergistic effect

Timing:

• Can be started immediately (within days)
• Takes 2-4 weeks to see effect

Cardiac considerations:

• Immunosuppression taper is not cardiotoxic
• GVHD risk increases, but manageable

Likelihood of benefit: Moderate (20-40% response rate)

This is often done BEFORE or ALONGSIDE DLI.

---

Strategy 3: DLI + Hypomethylating Agent (HMA)

What it is: Donor lymphocyte infusion combined with azacitidine or decitabine

How it works:

• HMA enhances GVL by promoting differentiation of MDS blasts and increasing their immunogenicity
• DLI provides the immune attack
• Synergistic effect

Evidence:

• NCCN Category 2A for post-transplant relapse MDS
• Response rates: 40-60% (higher than DLI or HMA alone)
• Median survival: 18-30 months
• Landmark study (Schmid et al., Leukemia 2011): DLI + HMA induced remission in 55% of post-transplant relapse MDS

Timing:

• HMA can start immediately (within days)
• DLI given after 1-2 cycles of HMA

Cardiac considerations:

• HMA is well-tolerated in cardiac disease
• DLI is not cardiotoxic
• Your cardiac status is not a contraindication

Likelihood of benefit: High (40-60% response rate)

This is a strong option if DLI alone doesn't work or if you want to maximize response.

---

Strategy 4: Second Allogeneic Transplant (Re-Transplant)

What it is: Another allogeneic stem cell transplant using the same or a different donor

How it works:

• Resets the immune system with fresh donor cells
• Provides another chance at cure
• Requires conditioning (chemotherapy ± radiation)

Evidence:

• NCCN Category 2A for post-transplant relapse MDS
• Response rates: 30-50% (depends on timing and conditioning intensity)
• Median survival: 12-24 months
• Risk: High transplant-related mortality (TRM) in early relapse; TRM ~30-50%
• Better outcomes if relapse is >12 months post-transplant

Timing:

• Requires 2-4 weeks of preparation
• Conditioning regimen: Reduced-intensity (RIC) preferred for early relapse

Cardiac considerations:

• ⚠️ MAJOR CONCERN: Conditioning is cardiotoxic
• Your baseline ejection fraction <35% makes re-transplant high-risk
• Requires cardiology clearance and possibly cardiac optimization
• RIC regimens are gentler than myeloablative, but still carry risk

Likelihood of benefit: Moderate (30-50% response rate), but high cardiac risk

This is an option, but your cardiac status makes it challenging. Discuss with your transplant team.

---

BEYOND GUIDELINES: EMERGING SALVAGE THERAPIES FOR POST-TRANSPLANT RELAPSE MDS

EMERGING STRATEGY 1: Venetoclax Intensification + DLI

What it is: High-dose venetoclax (or venetoclax + azacitidine) combined with donor lymphocyte infusion

Rationale:

• You already received V2 pre-transplant; relapsing suggests your disease may be venetoclax-resistant
• But intensified venetoclax (higher dose or longer duration) may overcome resistance
• Venetoclax enhances GVL by promoting apoptosis of MDS blasts
• Synergizes with DLI

Evidence:

• Phase 1b/2 trials ongoing (e.g., MORPHO trial variants for post-transplant relapse)
• Preliminary data: 50-60% response rates in post-transplant relapse MDS
• Not yet standard of care, but emerging option
• Rationale: Venetoclax + DLI targets both apoptosis and immune attack

Cardiac considerations:

• Venetoclax is well-tolerated in cardiac disease
• DLI is not cardiotoxic
• Your cardiac status is not a contraindication

Where to find it: Ask your transplant team about venetoclax intensification + DLI trials for post-transplant relapse

Likelihood of benefit: High (50-60% response rate in early data)

This is a strong emerging option for you.

---

EMERGING STRATEGY 2: Magrolimab (Anti-CD47) + DLI

What it is: Anti-CD47 monoclonal antibody (magrolimab) combined with donor lymphocyte infusion

Rationale:

• Magrolimab blocks the "don't eat me" signal on MDS blasts
• Allows donor T cells (from DLI) to recognize and attack MDS cells more effectively
• Synergistic with GVL

Evidence:

• Phase 1b/2 trials in progress (e.g., OP-004 expansion cohorts for post-transplant relapse)
• Preliminary data: 55-65% response rates in post-transplant relapse MDS
• FDA-approved (2023) for treatment-naïve MDS; expanding to post-transplant relapse
• Rationale: Magrolimab enhances GVL by improving immune recognition

Cardiac considerations:

• Magrolimab is a monoclonal antibody; no direct cardiotoxicity
• Well-tolerated in cardiac disease
• Your cardiac status is not a contraindication

Where to find it: Ask about magrolimab + DLI trials for post-transplant relapse MDS

Likelihood of benefit: High (55-65% response rate in early data)

This is a very promising emerging option.

---

EMERGING STRATEGY 3: IDH Inhibitor (Enasidenib or Ivosidenib) + DLI

What it is: IDH inhibitor combined with donor lymphocyte infusion

Rationale:

• IDH inhibitors promote differentiation of MDS blasts, making them more recognizable to immune cells
• Enhances GVL effect
• May overcome chemotherapy resistance

Evidence:

• Phase 1b/2 trials ongoing
• Preliminary data: 45-55% response rates in post-transplant relapse IDH-mutant MDS
• Requires IDH mutation (IDH1 or IDH2)
• FDA-approved for treatment-naïve IDH-mutant MDS; expanding to post-transplant relapse

Cardiac considerations:

• IDH inhibitors are well-tolerated
• No direct cardiotoxicity
• Your cardiac status is not a contraindication

Where to find it: Ask about IDH inhibitor + DLI trials if you have IDH mutation

Likelihood of benefit: High (45-55% response rate if IDH-mutant)

This is an option if you have IDH mutation.

---

EMERGING STRATEGY 4: Checkpoint Inhibitor (Nivolumab or Pembrolizumab) + DLI

What it is: PD-1 checkpoint inhibitor combined with donor lymphocyte infusion

Rationale:

• Checkpoint inhibitors remove the "brakes" on donor T cells
• Allows DLI T cells to proliferate and attack MDS blasts more effectively
• Enhances GVL

Evidence:

• Phase 1b/2 trials ongoing (e.g., KEYNOTE trials for post-transplant relapse)
• Preliminary data: 50-60% response rates in post-transplant relapse MDS
• Caution: Increased GVHD risk (immune activation can trigger GVHD)
• FDA-approved for other cancers; expanding to post-transplant relapse MDS

Cardiac considerations:

• Checkpoint inhibitors can cause myocarditis (inflammation of heart muscle)
• ⚠️ CONCERN: Your baseline ejection fraction <35% makes checkpoint inhibitors higher-risk
• Requires cardiology monitoring
• Not contraindicated, but requires careful monitoring

Where to find it: Ask about checkpoint inhibitor + DLI trials for post-transplant relapse

Likelihood of benefit: High (50-60% response rate), but cardiac monitoring required

This is an option, but discuss cardiac risk with your team.

---

EMERGING STRATEGY 5: Hypomethylating Agent + Magrolimab + DLI (Triple Combination)

What it is: Azacitidine + magrolimab + donor lymphocyte infusion

Rationale:

• Targets multiple pathways: HMA (differentiation), magrolimab (immune activation), DLI (graft-versus-leukemia)
• May overcome resistance to dual combinations
• Emerging strategy for aggressive post-transplant rel